Opendata, web and dolomites

OncoSeq

OncoSeq: an innovative single-cell system for immunomonitoring

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OncoSeq project word cloud

Explore the words cloud of the OncoSeq project. It provides you a very rough idea of what is the project "OncoSeq" about.

cells    flow    prototype    infiltrating    once    quantity    simultaneous    validated    cancer    transcriptome    readout    phenotype    infiltrate    specialising    seq    single    rna    generation    ngs    exist    markets    sequencing    immunotherapies    adapt    cytometer    creation    clinical    decision    licensing    microfluidics    immunity    prognosis    vital    markers    diagnostic    entirely    diagnosis    disease    industrial    tumor    evoevo    site    le    immuno    oncology    mass    immune    fluorescence    tens    patient    prognostic    internal    sale    ultimately    genotype    context    droplet    marker    multiplexing    100s    company    stratification    monitoring    resolution    biopsy    maps    cytof    cytometry    output    follow    quality    strategies    tool    tumour    instruments    oncoseq    circulating    central    immunotherapy    transcriptomic    liquid    phenotypic    plan    transferred    host    molecular    progression    create    powerful    spectrometry    throughput    erc    cell    consumables    thousands    barcoding    capacity    plays   

Project "OncoSeq" data sheet

The following table provides information about the project.

Coordinator
PARMENIDES STIFTUNG 

Organization address
address: KIRCHPLATZ 1
city: MUNCHEN
postcode: 82049
website: www.parmenides-foundation.org

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2018-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PARMENIDES STIFTUNG DE (MUNCHEN) coordinator 41˙250.00
2    ECOLE SUPERIEURE DE PHYSIQUE ET DECHIMIE INDUSTRIELLES DE LA VILLE DEPARIS FR (PARIS) participant 108˙750.00

Map

 Project objective

Host immunity plays a central and complex role in tumour progression, and the quality and quantity of immune infiltrate at the tumour site is used as a prognostic marker of cancer progression. Therefore, detailed single-cell analysis of tumor infiltrating immune cells, and ultimately liquid biopsy of circulating immune cells, is of vital importance for the development of new and improved immunotherapy strategies, and for diagnosis, prognosis, patient stratification and follow-up. We propose in OncoSeq to adapt the droplet barcoding microfluidics system, an output from the ERC EVOEVO project, to develop a novel “molecular cytometer” for high-throughput transcriptomic and phenotypic analysis, at the single-cell level, of tumor infiltrating or circulating immune cells. Readout of genotype and phenotype will be entirely based on next generation sequencing (NGS) allowing higher phenotypic multiplexing capacity (100s of phenotypic markers) than fluorescence (Flow cytometry) or mass spectrometry (CyTOF) based approaches (≤40 markers) and simultaneous RNA-sequencing (RNA-seq), allowing the creation of high-resolution phenotype-transcriptome maps for tens of thousands of single cells. This will be a powerful tool for cancer prognosis, clinical decision making and monitoring of disease progression, especially in the context of immunotherapy. So far, no such diagnostic instruments, enabling high-throughput single-cell phenotypic and transcriptomic analysis, exist. The technology developed will be transferred to our industrial partner through licensing for internal development of novel immunotherapies. In addition, once the prototype system is fully validated, we plan, with our industrial partners, to create a new company specialising in the sale of instruments and associated consumables for clinical single-cell immuno-monitoring for the research and clinical oncology markets.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOSEQ" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCOSEQ" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More  

UltimateRB (2019)

Direct numerical simulations towards ultimate turbulence

Read More